— Why it moved
Why ENTX Stock Doubled, Then Fizzled Today — June 22, 2026
Genuine FDA news doubled the stock by midday. The spike topped the same minute Stock Pulse flagged it, then gave nearly all of it back into the close.
## What moved it Real news for once. Entera Bio said the FDA gave positive feedback on its registrational Phase 3 protocol for EB613, an oral parathyroid-hormone tablet for postmenopausal osteoporosis. One placebo-controlled trial in about 750 women, hip bone density at 12 months as the endpoint, and a clearer path to an NDA filing.
## The mechanics Not a microfloat toy this time. A 40M-share float and a ~$60M cap, but volume ran to about 51M shares against a 30-day average under 100K. When a sleepy biotech gets a de-risking headline, the first hours belong to momentum chasers, and they left as fast as they arrived.
## Numbers - Cap: ~$60M / float: 40M - Day volume: ~51M (30-day avg under 0.1M) - Prev close: $1.21 → intraday peak $2.68, +121% - 52w range: $0.91–$3.22
## Where it ended up Stock Pulse flagged it at 12:32 PM at $2.64. That minute was the top: $2.68, +1.5%, and it never traded there again. The stock slid all afternoon and closed at $1.49, 44% below the alert, though still up 23% on the day.
## Reality check - The alert fired into the exact top of the spike. Everything after it was downhill. - Clinical-stage, no approved product. The Phase 3 still has to be funded, run, and passed. - This already happened. It's a breakdown of why it ran, not a reason to buy it.